Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts

Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts

Saved in:

Bibliographic Details
Main Authors:	Sean J. Barbour, Rosanna Coppo, Jonathan Barratt, Lee Er, Richard Lafayette, Hiddo J.L. Heerspink, Dana V. Rizk, Adrian Liew, Vivekanand Jha, Hong Zhang, Yusuke Suzuki, Hernan Trimarchi, Daniel C. Cattran
Format:	Article
Language:	English
Published:	Elsevier 2025-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024925000506
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Erratum to “Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts” [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1283-1287]
by: Sean J. Barbour, et al.
Published: (2025-07-01)

Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy
by: Hiddo J.L. Heerspink, et al.
Published: (2025-01-01)

Corrigendum to “Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy” [Volume 10, Issue 1, January 2025, Pages 217-226]
by: Hiddo J.L. Heerspink, et al.
Published: (2025-04-01)

IgA Nephropathy in the Elderly
by: Dana V. Rizk, et al.
Published: (2025-08-01)

WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT
by: Bruce Hendry, et al.
Published: (2025-02-01)

WCN24-1414 ORIGIN 3: PIVOTAL PHASE 3 STUDY EVALUATING EFFECT OF ATACICEPT VS PLACEBO ON PROTEINURIA AND RENAL FUNCTION PRESERVATION IN IGA NEPHROPATHY
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN25-844 FELZARTAMAB FOR IgA NEPHROPATHY: FINAL RESULTS OF THE IGNAZ STUDY
by: Uptal Patel, et al.
Published: (2025-02-01)

Corticosteroid Effects in IgA Nephropathy by Baseline Proteinuria and Estimated GFR
by: Dana Kim, et al.
Published: (2025-06-01)

Novel Treatment Paradigms: Primary IgA Nephropathy
by: Haresh Selvaskandan, et al.
Published: (2024-02-01)

WCN24-1294 ATACICEPT REDUCES HEMATURIA AND SERUM GD-IGA1, BOTH ASSOCIATED WITH LONG-TERM RENAL OUTCOMES IN IGA NEPHROPATHY: 36-WEEK RESULTS FROM THE PHASE 2B ORIGIN STUDY
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN24-1837 BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY
by: Hernán Trimarchi, et al.
Published: (2024-04-01)

Unconventional T Cells in IgA Nephropathy
by: Zizhang Sheng, et al.
Published: (2025-02-01)

WCN24-1197 EFFICACY AND SAFETY OF RAVULIZUMAB IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL IN IgA NEPHROPATHY
by: Jonathan Barratt, et al.
Published: (2024-04-01)

Is Childhood IgA Nephropathy Different From Adult IgA Nephropathy? A Narrative Review
by: Areefa Alladin-Karan, et al.
Published: (2025-03-01)

WCN24-1863 Towards an IgA Nephropathy Atlas
by: Julio Saez-Rodriguez, et al.
Published: (2024-04-01)

Application of hydroxychloroquine for IgA nephropathy
by: Xiao Yong-zhen, et al.
Published: (2021-01-01)

Effect of Telitacicept on Circulating Gd-IgA1 and IgA-Containing Immune Complexes in IgA Nephropathy
by: Jincan Zan, et al.
Published: (2024-04-01)

Corrigendum to “Is childhood IgA nephropathy different from adult IgA nephropathy? A narrative review”
Published: (2025-07-01)

The Prevalence and Characteristics of IgA Antibodies to β2-Spectrin and CBX3 in Immunoglobulin A Nephropathy
by: Ayako Koizumi, et al.
Published: (2025-05-01)

Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy
by: Jingyi Li, et al.
Published: (2024-10-01)

Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review.
by: Qiang Sun, et al.
Published: (2016-01-01)

Carboxymethyl-lysine is a Prominent Target of Circulating IgA in IgA Nephropathy
by: Sara Alibrandi, et al.
Published: (2025-07-01)

Aberrantly Glycosylated IgA1 as a Factor in the Pathogenesis of IgA Nephropathy
by: Mototsugu Tanaka, et al.
Published: (2011-01-01)

WCN24-1868 ASSIST: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER TRIAL OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN) ON SGLT2I
by: Irene L. Noronha, et al.
Published: (2024-04-01)

Serum Cytokine Profile in IgA Nephropathy
by: Friederike Selbach, MD, et al.
Published: (2025-02-01)

Serial Galactose-Deficient IgA1 Levels in Children with IgA Nephropathy and Healthy Controls
by: John T. Sanders, et al.
Published: (2017-01-01)

Serum Galactose-Deficient IgA1 Level Is Not Associated with Proteinuria in Children with IgA Nephropathy
by: M. Colleen Hastings, et al.
Published: (2012-01-01)

WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

Significance of serum IgA/C3 ratio in the diagnosis and prognosis of IgA nephropathy
by: XIE Wei-ji, et al.
Published: (2019-01-01)

Opportunities and challenges in the treatment of IgA nephropathy
by: Yang Yang, et al.
Published: (2025-07-01)

Characterisation of IgA Nephropathy in an Australian Cohort
by: Shriram Swaminathan, et al.
Published: (2025-01-01)

Research advances on the pathogenesis of IgA nephropathy
by: Lu Fang-cao, et al.
Published: (2022-02-01)

Influencing factors of IgA nephropathy combined with hyperuricemia and a nomogram to predict the risk of hyperuricemia in IgA nephropathy patients
by: Zhou Jie, et al.
Published: (2025-01-01)

Influencing factors of IgA nephropathy combined with hyperuricemia and a nomogram to predict the risk of hyperuricemia in IgA nephropathy patients
by: Zhou Jie, et al.
Published: (2025-01-01)

LIF/JAK2/STAT1 Signaling Enhances Production of Galactose-Deficient IgA1 by IgA1-Producing Cell Lines Derived From Tonsils of Patients With IgA Nephropathy
by: Koshi Yamada, et al.
Published: (2024-02-01)

Relationship between Gd-IgA1 and TNFR1 in IgA nephropathy and IgA vasculitis nephritis in children – multicenter study
by: Małgorzata Mizerska-Wasiak, et al.
Published: (2021-08-01)

WCN25-4466 Baseline parameters of IgA Nephropathy Using the Oxford MEST Score: Insights from the I-TANGIBLE Registry
by: Kavita Yadav, et al.
Published: (2025-02-01)

WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN25-778 AFFINITY study: 1-year results of atrasentan in IgA nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

Serum IgA/C3 ratio as a diagnostic and prognostic biomarker for IgA nephropathy
by: Anitha Swamy, et al.
Published: (2025-08-01)